Efficacy and safety of dutasteride in the treatment of alopecia: a comprehensive review.

IF 2.5 3区 医学 Q3 PHARMACOLOGY & PHARMACY
Expert Opinion on Pharmacotherapy Pub Date : 2025-03-01 Epub Date: 2025-02-03 DOI:10.1080/14656566.2025.2461169
Aditya K Gupta, Mesbah Talukder
{"title":"Efficacy and safety of dutasteride in the treatment of alopecia: a comprehensive review.","authors":"Aditya K Gupta, Mesbah Talukder","doi":"10.1080/14656566.2025.2461169","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Alopecia affects many individuals, with androgenetic alopecia (AGA) being the most common form in both men and women. The exact etiology of AGA is unclear. The systemic treatments of AGA include 5-alpha reductase inhibitors (finasteride, dutasteride) and low-dose oral minoxidil.</p><p><strong>Areas covered: </strong>The article comprehensively reviews dutasteride's pharmacokinetics, pharmacodynamics, clinical efficacy, and side effects to support clinicians in prescribing it for alopecia.</p><p><strong>Expert opinion: </strong>Studies show dutasteride to be more effective than finasteride for AGA, with both drugs having similar safety profiles. In our view, clinicians should consider topical minoxidil and oral finasteride as first-line treatments, as they are well-studied for male and female AGA (finasteride is off label in females and should only be considered in post-menopausal females). If these options are ineffective, oral dutasteride may be considered off-label for greater efficacy in males and post-menopausal females. However, dutasteride can reduce sperm count and motility, potentially affecting fertility in men with preexisting fertility issues. Men whose partners are pregnant should avoid dutasteride.</p>","PeriodicalId":12184,"journal":{"name":"Expert Opinion on Pharmacotherapy","volume":" ","pages":"367-379"},"PeriodicalIF":2.5000,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Opinion on Pharmacotherapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14656566.2025.2461169","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/2/3 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Alopecia affects many individuals, with androgenetic alopecia (AGA) being the most common form in both men and women. The exact etiology of AGA is unclear. The systemic treatments of AGA include 5-alpha reductase inhibitors (finasteride, dutasteride) and low-dose oral minoxidil.

Areas covered: The article comprehensively reviews dutasteride's pharmacokinetics, pharmacodynamics, clinical efficacy, and side effects to support clinicians in prescribing it for alopecia.

Expert opinion: Studies show dutasteride to be more effective than finasteride for AGA, with both drugs having similar safety profiles. In our view, clinicians should consider topical minoxidil and oral finasteride as first-line treatments, as they are well-studied for male and female AGA (finasteride is off label in females and should only be considered in post-menopausal females). If these options are ineffective, oral dutasteride may be considered off-label for greater efficacy in males and post-menopausal females. However, dutasteride can reduce sperm count and motility, potentially affecting fertility in men with preexisting fertility issues. Men whose partners are pregnant should avoid dutasteride.

杜他雄胺治疗脱发的有效性和安全性:一项全面的综述。
简介:脱发影响许多个体,雄激素性脱发(AGA)是男性和女性中最常见的形式。AGA的确切病因尚不清楚。AGA的全身治疗包括5- α还原酶抑制剂(非那雄胺、度他雄胺)、小剂量口服米诺地尔。涵盖领域:文章全面回顾了度他雄胺的药代动力学、药效学、临床疗效和副作用,以支持临床医生为脱发患者开处方。专家意见:研究表明杜他雄胺比非那雄胺对AGA更有效,两种药物具有相似的安全性。在我们看来,临床医生应该考虑局部米诺地尔和口服非那雄胺作为一线治疗方法,因为它们在男性和女性AGA中都有很好的研究(非那雄胺在女性中是标签外的,应该只考虑绝经后的女性)。如果这些选择无效,口服度他雄胺可能被认为是标签外的,对男性和绝经后女性更有效。然而,杜他雄胺可以减少精子数量和活力,潜在地影响有生育问题的男性的生育能力。伴侣怀孕的男性应避免使用度他雄胺。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
5.60
自引率
3.10%
发文量
163
审稿时长
4-8 weeks
期刊介绍: Expert Opinion on Pharmacotherapy is a MEDLINE-indexed, peer-reviewed, international journal publishing review articles and original papers on newly approved/near to launch compounds mainly of chemical/synthetic origin, providing expert opinion on the likely impact of these new agents on existing pharmacotherapy of specific diseases.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信